Mark Collins Ph.D.
Mark Collins, Ph.D. has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.
D.J. Kleinbaum, Ph.D
D.J. Kleinbaum, Ph.D. is the Co-founder and Co-CEO at Emerald Cloud Lab & Emerald Therapeutics. Dr Kleinbaum received his B.S. in Biological Sciences from Carnegie Mellon University and his Ph.D. in Chemistry from Stanford University. While at Stanford, he designed and synthesized new architectures for DNA-templated reactions that can be used to detect RNA in living cells under the direction of Professor Eric Kool. He is an inventor on five patents and has been published in the Journal of the American Chemical Society, Bioconjugate Chemistry, and Chemical Communications.
Tom Rush, Ph.D.
Tom Rush, Ph.D. is the CSO of the ATOM Consortium, and Head of Biology Acceleration at GSK. Dr Rush is a leader in the Pharmaceuticals and Biotechnology industries with 18+ yrs experience and a passion for discovering technology & medicines that will save and improve human lives. He has personally contributed to to more than 15 development candidates, 4 IND’s and 2 marketed products across several disease areas. His leadership and expertise throughout the Discovery and Development phases spans multiple areas, including: High Throughput Screening, Clinical PK and Pharmacology, Computational Biology & Chemistry, Genetics, Licensing/Due Diligence and External Innovation.
Brad Schwartz, M.D.
Website: Morgridge Institute for Research
Brad Schwartz, MD is the Chief Executive Officer of the Morgridge Institute for Research, a private, nonprofit research institute dedicated to interdisciplinary biomedical research in partnership with the University of Wisconsin-Madison. Dr. Schwartz is a physician-scientist whose research and clinical activities focus on hemostasis. Dr. Schwartz earned his undergraduate degree in chemistry at the University of Illinois at Urbana-Champaign and his MD from Rush University in Chicago. He completed his residency at UW-Madison and pursued postdoctoral research with Tom Edgington. His clinical training at Scripps Clinic was with Ernie Beutler, an iconic figure in hematology whose contributions spanned genetic diseases of red blood cells to bone marrow transplantation.